行情

RMTI

RMTI

Rockwell Medical
NASDAQ

实时行情|Nasdaq Last Sale

2.090
-0.010
-0.48%
盘后: 2.090 0 0.00% 16:00 11/15 EST
开盘
2.120
昨收
2.100
最高
2.140
最低
2.050
成交量
59.15万
成交额
--
52周最高
6.88
52周最低
1.810
市值
1.34亿
市盈率(TTM)
-3.3973
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明：分析师观点仅供投资者决策参考，不构成任何买卖投资建议。

EPS

RMTI 新闻

  • UPDATE: Piper Jaffray On Rockwell Medical Notes 'we do remain buyers of RMTI shares as we think this company's new management team remains in a solid position to launch IV Triferic next year'
  • Benzinga.3天前
  • UPDATE: Piper Jaffray Maintains Overweight On Rockwell Medical, Lowers Target To $6 Notes 'As Feared, Triferic IV Not TDAPA Eligible; Lowering Estimates Meaningfully'
  • Benzinga.3天前
  • Piper Jaffray Maintains Overweight on Rockwell Medical, Lowers Price Target to $6
  • Benzinga.3天前
  • Rockwell Medical, Inc. (RMTI) CEO Stuart Paul on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.3天前

更多

所属板块

生物技术和医学研究
+1.49%
制药与医学研究
+1.29%

热门股票

名称
价格
涨跌幅

RMTI 简况

Rockwell Medical, Inc. is a biopharmaceutical company. The Company is targeting end-stage renal disease and chronic kidney disease with products for the treatment of iron deficiency and hemodialysis. The Company is also a manufacturer of hemodialysis concentrates for dialysis providers and distributors. The Company’s renal drug therapy, Triferic, supports disease management initiatives. Triferic is therapy indicated to replace iron and maintain hemoglobin in hemodialysis patients via dialysate during each dialysis treatment. The Company has developed multiple formulations of Triferic: Dialysate Triferic and Intravenous Triferic (I.V. Triferic). Dialysate Triferic is the therapeutic indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients.
展开

Webull提供Rockwell Medical Inc的股票价格，实时市场报价，专业分析师评级，深度图表和免费的股票新闻，以帮助您做出投资决策。